-
21.
公开(公告)号:WO2021175453A1
公开(公告)日:2021-09-10
申请号:PCT/EP2020/056122
申请日:2020-03-06
申请人: SYMRISE AG
IPC分类号: A61K8/35 , A61K8/365 , A61K8/44 , A61K8/67 , A61K8/9794 , A61K31/196 , A61K36/899 , A61P17/18 , A61Q17/04
摘要: The present invention relates generally to: a composition comprising or consisting at least one avenanthramide or an analogue thereof or an oat extract comprising an avenanthramide or an analogue thereof with an improved stability; its cosmetic or medical use; the use of such composition for the preparation of foods, food supplements, cosmetic, pharmaceutical or veterinary preparations; and foods, food supplements, cosmetic, pharmaceutical or veterinary perparations comprising such a composition. Finally, the present invention relates to specific stabilizers for the stabilisation of avenantramide(s).
-
22.
公开(公告)号:WO2021175452A1
公开(公告)日:2021-09-10
申请号:PCT/EP2020/056120
申请日:2020-03-06
申请人: SYMRISE AG
发明人: LANGE, Sabine , HERRMANN, Martina , MEYER, Imke , BRUNCKE, Sebastian , JOPPE, Holger , PALANI, Kalpana
IPC分类号: A61K8/44 , A61K31/196 , A61P29/00 , A61K8/34 , A61Q5/00 , A61Q13/00 , A61Q15/00 , A61Q17/04 , A61Q19/00 , A61Q19/10
摘要: The present invention relates generally to: a composition comprising or consisting of an avenanthramide or an analogue thereof and at least one penetration enhancer with an improved skin penetration; a method for preparing said composition; the use of such compositions as cosmetics or pharmaceuticals; and cosmetics or pharmaceuticals comprising said composition.
-
公开(公告)号:WO2021172987A1
公开(公告)日:2021-09-02
申请号:PCT/NL2021/050125
申请日:2021-02-25
申请人: FERRING B.V.
IPC分类号: A61K31/196 , A61K9/00 , A61P19/02
摘要: Described herein are pharmaceutical compositions comprising diclofenac and therapeutic methods for using them effective with once daily administration.
-
公开(公告)号:WO2021087083A1
公开(公告)日:2021-05-06
申请号:PCT/US2020/057913
申请日:2020-10-29
发明人: GARZA, Luis , ISLAM, Mohameed , SLUSHER, Barbara , RAIS, Rana
IPC分类号: A61K31/167 , A61K31/17 , A61K31/196
摘要: Methods for the use of prodrugs of itaconic acid and 1- and 4-methyl itaconic acid for inducing hair growth and treating an inflammatory, or immune activation (adaptive or innate), skin condition or other condition associated with hair loss are disclosed.
-
公开(公告)号:WO2021069486A1
公开(公告)日:2021-04-15
申请号:PCT/EP2020/078104
申请日:2020-10-07
发明人: PLANZ, Oliver
IPC分类号: A61K31/166 , A61K31/196 , A61P31/14
摘要: The present invention relates to MEK inhibitors that are capable of displaying one or more beneficial therapeutic effects. The MEK inhibitors can be used in the prevention and/or treatment of hantavirus infection.
-
公开(公告)号:WO2020258971A1
公开(公告)日:2020-12-30
申请号:PCT/CN2020/083067
申请日:2020-04-02
申请人: 深圳市三启药物开发有限公司
IPC分类号: C07D277/56 , C07D277/46 , C07D277/82 , C07D213/75 , C07D213/85 , C07D211/58 , C07D217/06 , C07D295/185 , C07C251/76 , A61K31/426 , A61K31/428 , A61K31/4402 , A61K31/472 , A61K31/4465 , A61K31/5375 , A61K31/44 , A61K31/196 , A61P19/10 , A61P19/08
摘要: 本发明提供了一类全新的腙酰胺类衍生物及其在制备抗骨质疏松药物中的应用,所述腙酰胺类衍生物的结构式如式(I)所示,是一类全新的具有抗骨质疏松效果的化合物。
-
公开(公告)号:WO2020155673A1
公开(公告)日:2020-08-06
申请号:PCT/CN2019/111940
申请日:2019-10-18
申请人: 中国药科大学
IPC分类号: A61K31/194 , A61K31/704 , A61K31/136 , A61K31/403 , A61K31/337 , A61K31/519 , A61K31/196 , A61K31/4178 , A61K31/4745 , A61K47/10 , A61K47/46 , A61K47/22 , A61K47/26 , A61P35/00
摘要: 三元复合纳米体系及其制备方法和应用,所述体系包括铁化合物、含苯环的小分子抗肿瘤活性化合物和多酚类化合物,三者的重量比为1-4∶2-10∶5-20。相对于现有技术,仅通过物理组装手段可将不同的小分子化合物或药物进行稳定组装,所形成的复合纳米药物不仅小分子抗肿瘤活性化合物的抗肿瘤治疗作用,还具有铁化合物与多酚类化合物基于胞内芬顿反应而介导的铁死亡治疗效应,此外,形成的新型复合纳米药物还具有突出的光热效应,可整合化疗、铁死亡治疗与光热疗法为一体,三者协同作用,相互增效,达到多位一体的联合抗肿瘤治疗效果。
-
公开(公告)号:WO2020084105A2
公开(公告)日:2020-04-30
申请号:PCT/EP2019/079133
申请日:2019-10-25
IPC分类号: A61K31/196 , A61K31/403 , A61K31/405 , A61K31/616 , A61P35/00
摘要: The invention relates to a composition comprising one or more inhibitors capable of inhibiting at least two of cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and lipoxygenase or a composition comprising one or more inhibitors capable of inhibiting an enzyme with arachidonate-Co A ligase activity, specifically long-chain-fatty-acid-Co A ligase (ACSL) 1, ACSL3, ACSL4, ACSL5, ACSL6, SLC27A2 or ACSBG2, or a combination thereof for use in selectively eliminating senescent cells. The invention further relates to an in vitro method of identifying senescent cells in a subject and to a method of identifying candidate compounds for the selective elimination of senescent cells.
-
公开(公告)号:WO2020035546A1
公开(公告)日:2020-02-20
申请号:PCT/EP2019/071881
申请日:2019-08-14
IPC分类号: C07C235/68 , A61K31/196 , A61P37/08 , A61P17/00
摘要: The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.
-
公开(公告)号:WO2020020790A1
公开(公告)日:2020-01-30
申请号:PCT/EP2019/069564
申请日:2019-07-19
发明人: STROYER, Anke , LOBBACK, Carmen , SERNO, Peter , JACOBS, Tia
IPC分类号: A61K9/20 , A61K31/192 , A61K31/196 , A61P3/10 , A61P7/02 , A61P9/00 , A61P19/08 , A61P25/28
摘要: Die vorliegende Erfindung betrifft oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung enthaltend (3S)-3-(4-Chlor-3-{[(2S,3R)-2-(4-chlorphenyl)-4,4,4-trifluor-3- methylbutanoyl]amino}phenyl)-3-cyclopropylpropansäure sowie Verfahren zur Herstellung der Darreichungsformen und ihre Verwendung zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von kardialen, renalen, pulmonalen und ophthalmologischen Erkrankungen, Erkrankungen des Zentralnervensystems, fibrotischen und inflammatorischen Erkrankungen und Stoffwechselerkrankungen.
-
-
-
-
-
-
-
-
-